Corcept Therapeutics Incorporat (CORT) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. At $58.22, A.R:R 1.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 1.5): -1.0; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.1).
Corcept Therapeutics markets Korlym (mifepristone) and its authorized generic for Cushing's syndrome in the U.S., generating substantially all its revenue from these two products. New specialty pharmacy Curant Health (as of Q4 2025) collects >99% of Corcept's insurance revenue;... Read more
Sell if holding. At $58.22, A.R:R 1.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 1.5): -1.0; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.1). Chart setup: Death cross but MACD improving, RSI 75. Score 4.9/10, high confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 72d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Corcept Therapeutics Incorporat
Latest news
- Lifyorli’s Pivotal ROSELLA Data and FDA Nod Might Change The Case For Investing In Corcept (CORT) - Sahm — Sahm positive
- Corcept Therapeutics (CORT) Inspires Confidence with ROSELLA Phase 3 Survival Data - Insider Monkey — Insider Monkey positive
- Corcept Earnings: What To Look For From CORT - StockStory — StockStory neutral
- Why investors strapped a rocket to Corcept Therapeutics stock on Wednesday - MSN — MSN positive
- Why Corcept Therapeutics Stock Is Sinking Today - TipRanks — TipRanks negative
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $58.22, A.R:R 1.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 1.5): -1.0; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.1). Chart setup: Death cross but MACD improving, RSI 75. Prior stop was $54.14. Score 4.9/10, high confidence.
Take-profit target: $68.73 (+18.1% upside). Prior stop was $54.14. Stop-loss: $54.14.
V7 low-quality RISK_OFF penalty: -0.5 (Q=5.1); Leverage penalty (D/E 1.5): -1.0; Consecutive earnings misses (2).
Corcept Therapeutics Incorporat trades at a P/E of 157.5 (forward 33.8). TrendMatrix value score: 5.1/10. Verdict: Sell.
12 analysts cover CORT with a consensus score of 3.9/5. Average price target: $79.
What does Corcept Therapeutics Incorporat do?Corcept Therapeutics markets Korlym (mifepristone) and its authorized generic for Cushing's syndrome in the U.S.,...
Corcept Therapeutics markets Korlym (mifepristone) and its authorized generic for Cushing's syndrome in the U.S., generating substantially all its revenue from these two products. New specialty pharmacy Curant Health (as of Q4 2025) collects >99% of Corcept's insurance revenue; its pipeline includes relacorilant (CRL received for Cushing's in Dec 2025; PDUFA July 2026 for ovarian cancer).